Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Epsilon-aminocaproic acid (EACA).

J D Griffin, L Ellman

    Seminars in Thrombosis and Hemostasis
    |January 1, 1978
    PubMed
    Summary
    This summary is machine-generated.

    Epsilon-aminocaproic acid (EACA) is a key antifibrinolytic drug used to control bleeding. While effective in various situations, its use requires careful consideration of potential thrombotic risks.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Editorial Expression of Concern: Discovery of a BTK/MNK dual inhibitor for lymphoma and leukemia.

    Leukemia·2026
    Same author

    Distinct alterations in probabilistic reversal learning across at-risk mental state, first episode psychosis and persistent schizophrenia.

    Scientific reports·2024
    Same author

    Correction: Precision weighting of cortical unsigned prediction error signals benefits learning, is mediated by dopamine, and is impaired in psychosis.

    Molecular psychiatry·2020
    Same author

    Precision weighting of cortical unsigned prediction error signals benefits learning, is mediated by dopamine, and is impaired in psychosis.

    Molecular psychiatry·2020
    Same author

    Correction: AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL.

    British journal of cancer·2019
    Same author

    Discovery of a highly potent FLT3 kinase inhibitor for FLT3-ITD-positive AML.

    Leukemia·2016
    Same journal

    Full- vs Reduced-Dose Direct Oral Anticoagulants for Extended Treatment of Cancer-Associated Thrombosis: A Multicenter Retrospective Cohort Study.

    Seminars in thrombosis and hemostasis·2026
    Same journal

    Too Old for PESI?: Risk Stratification of Octogenarians with Pulmonary Embolism in the Emergency Department.

    Seminars in thrombosis and hemostasis·2026
    Same journal

    Acute Management and Bleeding Outcomes in Pediatric Pulmonary Embolism: A Large Single-Center Retrospective Cohort Study.

    Seminars in thrombosis and hemostasis·2026
    Same journal

    Red Blood Cells in Hemostasis and Thrombosis: Mechanisms, Interactions, and Clinical Implications.

    Seminars in thrombosis and hemostasis·2026
    Same journal

    Pediatric Pulmonary Infarction and Infarction-Like Pulmonary Injury: An Etiology-Oriented Narrative Review.

    Seminars in thrombosis and hemostasis·2026
    Same journal

    Comparison of the Coagulation Profile Following Treatment of Major Surgical Haemorrhage with Fresh Frozen Plasma or Fibrinogen Concentrate.

    Seminars in thrombosis and hemostasis·2026
    See all related articles

    Area of Science:

    • Pharmacology
    • Hematology

    Background:

    • Epsilon-aminocaproic acid (EACA) is a synthetic inhibitor of the plasmin-plasminogen system.
    • It is the sole potent antifibrinolytic agent commercially available in the United States.
    • EACA achieves effective blood levels via oral or intravenous administration and is highly concentrated in urine during excretion.

    Purpose of the Study:

    • To review the clinical applications of EACA in managing bleeding.
    • To highlight the potential benefits and risks associated with EACA use.
    • To emphasize the need to balance therapeutic advantages against serious complications.

    Main Methods:

    • Review of clinical literature on EACA.
    • Analysis of EACA's pharmacokinetic properties.
    • Assessment of reported side effects and clinical outcomes.

    Related Experiment Videos

    Main Results:

    • EACA is effective in controlling bleeding in subarachnoid hemorrhage, genitourinary bleeding, and dental surgery in hemophiliacs.
    • Potential efficacy is noted in menorrhagia, gastrointestinal bleeding, obstetrical bleeding, and post-cardiac/thoracic surgery bleeding.
    • Major side effects include hypotension, cardiac arrhythmias, rhabdomyolysis, and thrombus generation.

    Conclusions:

    • The use of EACA necessitates weighing its benefits against potential serious complications, particularly widespread thrombosis.
    • The risk of thrombotic events may be elevated in patients with a predisposition to thrombosis.
    • Careful patient selection and monitoring are crucial when administering EACA.